Cronos Group Inc
TSX:CRON
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cronos Group Inc
TSX:CRON
|
CA |
|
Endeavour Group Ltd
ASX:EDV
|
AU |
|
L
|
Litu Holdings Ltd
HKEX:1008
|
CN |
|
Delta Djakarta Tbk PT
IDX:DLTA
|
ID |
|
Ulusoy Un Sanayi ve Ticaret AS
IST:ULUUN.E
|
TR |
|
Shenzhen Ridge Engineering Consulting Co Ltd
SZSE:300977
|
CN |
|
Latch Inc
OTC:LTCH
|
US |
|
Caica Digital Inc
TSE:2315
|
JP |
|
Vimeo Inc
NASDAQ:VMEO
|
US |
|
E
|
Energia Latina SA
SGO:ENLASA
|
CL |
|
Bank First Corp
NASDAQ:BFC
|
US |
|
Vef AB (publ)
STO:VEFAB
|
SE |
|
P
|
Pharmesis International Ltd
SGX:BFK
|
CN |
|
MTG Co Ltd
TSE:7806
|
JP |
|
L
|
Langold Real Estate Co Ltd
SZSE:002305
|
CN |
|
Banco do Nordeste do Brasil SA
BOVESPA:BNBR3
|
BR |
|
N
|
NewGLab Pharma Co Ltd
KOSDAQ:214870
|
KR |
|
S
|
Song Da No 11 JSC
VN:SJE
|
VN |
Cronos Group Inc
Cronos Group, Inc. engages in the production and distribution of cannabis. The company is headquartered in Toronto, Ontario. The company went IPO on 2014-05-07. The firm is focused on cannabis research, technology and product development. The Company’s portfolio includes PEACE NATURALS, COVE, Spinach, Lord Jones, Happy Dance and PEACE+. PEACE NATURALS a global wellness platform. The COVE and Spinach are adult-use brands. The Lord Jones, Happy Dance and PEACE+ are hemp-derived cannabidiol (CBD) brands. The Company’s segments include United States and Rest of World. The United States operating segment consists of the manufacture and distribution of hemp-derived CBD infused products. The Rest of World operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. The Company’s subsidiaries include Cronos Israel G.S. Cultivation Ltd, Cronos Israel G.S. Manufacturing Ltd., Cronos Israel G.S. Store Ltd. and Cronos Israel G.S. Pharmacy Ltd.
Cronos Group, Inc. engages in the production and distribution of cannabis. The company is headquartered in Toronto, Ontario. The company went IPO on 2014-05-07. The firm is focused on cannabis research, technology and product development. The Company’s portfolio includes PEACE NATURALS, COVE, Spinach, Lord Jones, Happy Dance and PEACE+. PEACE NATURALS a global wellness platform. The COVE and Spinach are adult-use brands. The Lord Jones, Happy Dance and PEACE+ are hemp-derived cannabidiol (CBD) brands. The Company’s segments include United States and Rest of World. The United States operating segment consists of the manufacture and distribution of hemp-derived CBD infused products. The Rest of World operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. The Company’s subsidiaries include Cronos Israel G.S. Cultivation Ltd, Cronos Israel G.S. Manufacturing Ltd., Cronos Israel G.S. Store Ltd. and Cronos Israel G.S. Pharmacy Ltd.
Record Revenue: Cronos reported record net revenue for both the fourth quarter and full year 2025, with Q4 net revenue up 47% year-over-year and full-year organic growth of 25%.
Margin Improvement: Gross margin for the year reached 43%, and Q4 gross margin improved by 670 basis points year-over-year to 36%.
Canadian Market Strength: Canadian net revenue grew 42% year-over-year in Q4, led by strong performance in flower, vapes, and edibles, with the Spinach brand becoming the #2 vape brand and maintaining leadership in edibles.
International Growth: Net revenue in Israel grew 52% year-over-year, marking the eighth consecutive quarter of record revenue, while other international markets saw 68% year-over-year growth.
M&A Activity: Cronos plans to acquire CanAdelaar, the leading cannabis company in the Netherlands’ legal adult-use market, for about $67.5 million, with closing expected in the first half of 2026.
Strong Balance Sheet: The company ended the quarter with $832 million in cash, cash equivalents, and short-term investments, and has no debt.
Outlook: Management expects continued strong performance in 2026, with easing supply constraints, ongoing innovation, and a focus on disciplined M&A and cost management.
